A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery
Condition(s) studied
Investigational drug(s) / intervention(s)
TachoSil: Adjunct to hemostasis
Surgicel Original: Adjunct to hemostasis
Study summary
The purpose of this clinical study is to assess the efficacy and safety of TachoSil compared to the widely known and used for \> 60 years local hemostatic product Surgicel Original as an adjunct to control mild to moderate soft tissue bleeding during surgery.
Eligibility
Primary outcome measure(s)
- Hemostatic success within 3 minutes — within 3 minutes of study intervention
Proportion of participants achieving hemostatic success at the target bleeding site (TBS) within 3 minutes after application of study intervention
Trial sites (9)
| Facility | City | Region | Status |
|---|---|---|---|
| Torrance Memorial | Torrance | California | Recruiting |
| St. Anthony Hospital | Lakewood | Colorado | Recruiting |
| Georgetown University | Washington D.C. | District of Columbia | Recruiting |
| University Of Chicago | Chicago | Illinois | Recruiting |
| Indiana University | Indianapolis | Indiana | Recruiting |
| University of Louisville | Louisville | Kentucky | Recruiting |
| Washington University | St Louis | Missouri | Recruiting |
| Atrium Health Carolinas Medical Center | Charlotte | North Carolina | Recruiting |
| The Ohio State University Medical Center | Columbus | Ohio | Recruiting |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06664775 on ClinicalTrials.gov ↗ ← All trials in the USA